The global Antinuclear Antibody Test Market is expanding as the prevalence and diagnosis of autoimmune disorders increase worldwide. Antinuclear antibody (ANA) tests are important laboratory tools used to support the evaluation of autoimmune conditions, particularly systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s syndrome, and scleroderma.
According to Fortune Business Insights, the global antinuclear antibody test market was valued at USD 41.89 million in 2025 and is expected to reach USD 47.67 million in 2026 and USD 134.13 million by 2034, exhibiting a CAGR of 13.81% during the forecast period.
Why is the Antinuclear Antibody Test Market Growing?
The rising prevalence and diagnosis of autoimmune diseases are major factors driving demand for ANA testing. Conditions such as rheumatoid arthritis and systemic lupus erythematosus require laboratory investigations to support clinical evaluation and disease management.
ANA testing is increasingly used for:
Key Market Trends Shaping Industry Growth
Increasing Prevalence of Autoimmune Diseases
The growing burden of autoimmune disorders is one of the most significant market trends. Rising diagnosis rates of diseases such as rheumatoid arthritis and systemic lupus erythematosus are increasing demand for laboratory-based autoimmune testing.
According to the report, WHO data published in June 2023 indicated that 70% of rheumatoid arthritis patients worldwide are women and 55% are older than 55 years, highlighting the importance of diagnosis among aging populations.
Growing Adoption of Automated Immunofluorescence
Automation is transforming ANA testing by reducing manual workload and improving laboratory throughput. Automated immunofluorescence systems can standardize sample processing, image acquisition, and interpretation workflows.